Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M59.5Revenue (TTM) $M9.5Net Margin (%)-166.1Altman Z-Score-6.9
Enterprise Value $M50.1EPS (TTM) $-3.1Operating Margin %-158.5Piotroski F-Score4
P/E(ttm)--Beneish M-Score0.2Pre-tax Margin (%)-166.1Higher ROA y-yN
Price/Book8.710-y EBITDA Growth Rate %--Quick Ratio3.6Cash flow > EarningsN
Price/Sales2.35-y EBITDA Growth Rate %16.9Current Ratio3.9Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-202.2Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)--Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M15.1ROIC % (ttm)--Gross Margin Increase y-yY

Gurus Latest Trades with NBY

Number of guru portfolios checked: 68.
No Entry found in the selected group of Gurus. You can

NBY is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


NBY: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Najafi RaminCEO, 10% Owner 2015-08-20Buy480$11.75-66.55view
Pioneer Pharma (Singapore) Pte10% Owner 2015-03-03Buy103,600$15-73.8view
SIECZKAREK MARK MDirector 2015-03-03Buy6,667$15-73.8view
Najafi RaminChairman 2015-03-03Buy6,667$15-73.8view
Najafi RaminChairman 2014-12-12Buy2,000$16.25-75.82view
PAULSON THOMAS JCFO 2014-12-12Buy400$17-76.88view
Stroman David W.SVP, Ophthalmic Product Devt. 2014-12-12Buy400$16.5-76.18view
Najafi RaminChairman 2014-12-11Buy800$15-73.8view
PAULSON THOMAS JCFO 2014-12-09Buy400$16.75-76.54view
Najafi RaminChairman 2014-12-05Buy1,000$16.25-75.82view

Press Releases about NBY :

Quarterly/Annual Reports about NBY:

News about NBY:

Articles On GuruFocus.com
NovaBay Pharmaceuticals Inc. (NBY) Chairman Ramin Najafi buys 1,000 Shares Aug 28 2009 

More From Other Websites
NovaBay to Present at LD Micro Main Event Dec 01 2016
MULTIMEDIA UPDATE - NovaBay's Avenova Is Breakthrough in Fight Against Contact Lens Intolerance Nov 29 2016
NovaBay's Avenova Is Breakthrough in Fight Against Contact Lens Intolerance Nov 29 2016
Five Stocks Under $5.00 for December (NAK, GGB) Nov 23 2016
NOVABAY PHARMACEUTICALS, INC. Financials Nov 18 2016
NovaBay Pharmaceuticals, Inc. :NBY-US: Earnings Analysis: Q3, 2016 By the Numbers : November 14,... Nov 14 2016
NovaBay Pharmaceuticals Reports 2016 Third Quarter Financial Results Nov 10 2016
NOVABAY PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report Nov 10 2016
NovaBay Pharmaceuticals Reports 2016 Third Quarter Financial Results Nov 10 2016
NovaBay Pharmaceuticals to Hold Third Quarter 2016 Conference Call on November 10 Nov 04 2016
NovaBay Pharmaceuticals to Hold Third Quarter 2016 Conference Call on November 10 Nov 03 2016
NOVABAY PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Oct 31 2016
NovaBay Pharmaceuticals Successfully Regains Compliance with NYSE Continued Listing Requirements Oct 31 2016
NovaBay Pharmaceuticals Successfully Regains Compliance with NYSE Continued Listing Requirements Oct 31 2016
NOVABAY PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events Oct 24 2016
Eyelid Hygiene Cleanser Called "Avenova(R) with Neutrox(R)" Offers Help for Tired, Aging Eyes Oct 11 2016
NovaBay Pharmaceuticals Receives $7 Million from Early Warrant Exercise Oct 03 2016
NovaBay Pharmaceuticals Receives $7 Million from Early Warrant Exercise Oct 03 2016
NOVABAY PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement,... Sep 30 2016
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Breaches of... Sep 23 2016
TerraForm Power Inc (TERP) and Three Other Stocks Trading Higher on Positive News; Community Health... Sep 19 2016
New Therapy Introduced for Chronic Dry Eye Sep 19 2016
NovaBay Pharmaceuticals’ Auriclosene® Demonstrates Statistically Significant and Clinically... Sep 19 2016
NovaBay Pharmaceuticals’ Auriclosene® Demonstrates Statistically Significant and Clinically... Sep 19 2016
NovaBay Pharmaceuticals’ Neutrox® Product Line Receives CE Mark and ISO Certification for the... Sep 12 2016
NovaBay Pharmaceuticals’ Neutrox® Product Line Receives CE Mark and ISO Certification for the... Sep 12 2016
NovaBay Pharmaceuticals to Present at the Rodman & Renshaw Global Investment Conference Sep 06 2016
NOVABAY PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement,... Aug 26 2016
NovaBay Pharmaceuticals Reports 2016 Second Quarter Financial Results Aug 11 2016
NovaBay Pharmaceuticals to Hold Second Quarter 2016 Conference Call on August 11 Aug 04 2016
NovaBay Pharmaceuticals Completes $11.8 Million Private Placement Aug 02 2016
NovaBay Pharmaceuticals Appoints Mark M. Sieczkarek President and Chief Executive Officer Jun 13 2016
NovaBay Pharmaceuticals Reports 2016 First Quarter Financial Results May 12 2016
NovaBay Pharmaceuticals Appoints Todd Zavodnick to its Board of Directors May 09 2016
NovaBay Pharmaceuticals to Hold First Quarter 2016 Conference Call on May 12 May 05 2016
Clinical Data Presented at ARVO Showing NovaBay’s Avenova Reduces Bacteria on Ocular Skin Surface... May 03 2016
NovaBay Pharmaceuticals Announces Agreement for Nearly $12 Million in Two-Tranche Private Placement Apr 06 2016
NovaBay Pharmaceuticals Announces Filing of Annual Report on Form 10-K Mar 22 2016
NovaBay Pharmaceuticals Expects Fourth Quarter 2015 Avenova Sales to Exceed $1.5 Million Jan 11 2016
NovaBay Pharmaceuticals Secures $3 Million Bridge Loan Jan 07 2016
NovaBay Declares Reverse Stock Split Dec 11 2015
China Pioneer Pharma Offers Free NeutroPhase to Victims Suffered Burns in the Explosion in Tianjin Aug 14 2015

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)